ZBTB7B Knockout cell line (A-375)

Gene knockout cell lines are generated using CRISPR-Cas9 based technology to precisely disrupt target genes, enabling functional genomics research, disease modeling, and target validation.

ZBTB7B (zinc finger and BTB domain containing 7B) encodes a zinc finger transcription factor that regulates lineage commitment of immature T-cell precursors. It promotes commitment toward the CD4 T-cell lineage and, in its absence, favors CD8 lineage commitment. ZBTB7B also functions as a transcriptional repressor of type I collagen genes, linking its activity to both T-cell development and regulation of extracellular matrix-related gene expression.

The A375 cell line is a highly characterized human malignant melanoma model derived from a 54-year-old female patient. As referenced in image_2f51f1.png, this adherent cell line demonstrates robust translational performance in in vivo xenograft studies, reliably producing rapidly growing amelanotic melanomas when inoculated into anti-thymocyte serum-treated NIH Swiss mice. Serving as a globally recognized preclinical oncology platform, it is extensively utilized for investigating melanoma disease progression, executing high-throughput screening of novel therapeutics, and studying targeted signaling pathways in skin cancers.

Each knockout cell line is validated by STR authentication, sterility testing (bacteria/fungi), and mycoplasma screening. Genotype is confirmed by two rounds of PCR and Sanger sequencing. Only clones that pass all QC criteria are released, ensuring reliable identity and performance for downstream applications.